2 Spoopy 4 You
Elder Millennial. Husband. Girl dad. Dog owner. IT Professional. Tech enthusiast. CSS tinkerer. Music lover. Huge Sleep Token and Bilmuri fan.
Non-practicing white person.
Grew up in MD. Lived in and around Baltimore for a long time. Currently living in VA with my wife, 3 youngest daughters, and our 2 dogs.
Admin of:
https://DMV.Community (Mastodon)
🚨 BREAKING: A new report titled 'They Walk Among Us' from the Ohio Immigrant Alliance documents 59 current and former ICE and CBP personnel charged with or convicted of serious crimes.
Key findings from the July 2026 report:
- 50 of the 59 documented agents (84.7%) were charged or convicted of sexual assault
- 37 cases involved child victims, with 35 specifically involving sexual assault against children
- CBP accounted for the majority of cases, while ICE cases had a higher proportion of minor victims
The report highlights systemic oversight failures, including rapid hiring pushes that bypassed full vetting and a December 2025 DOJ directive instructing PREA auditors to pause compliance enforcement across key safety standards.
Read the report: https://ohioimmigrant.org/blog/2026/7/22/they-walk-among-us
The environmental cost of running LLMs keeps climbing, but a few inference providers are running on 100% clean energy out of the box:
- Regolo (https://regolo.ai/sustainable-ai/) EU-hosted GPU clusters running on wind and solar power, using zero-water cooling.
- GreenPT (https://greenpt.com/api) European OpenAI-compatible API powered 100% by renewables in ISO-certified datacenters.
- Riveon (https://riveon.io/) Swiss provider with Finnish GPU sites powered 100% by renewables, offering OpenAI-compatible endpoints.
- Upgreat (https://www.upgreat.ai/) Carbon-aware EU compute that schedules workloads around clean energy windows from on-site solar farms.
Good options if you want clean compute for open-weights inference without relying on carbon offsets.
#AI #GreenTech #OpenSource #Sustainability #MachineLearning #Tech
💊 A viral video calls benfotiamine (fat-soluble vitamin B1) a "revolutionary" anti-inflammatory breakthrough. The real story is more complicated.
The video references a real June 2026 study where researchers used computational drug repurposing to identify benfotiamine as a P2Y14R antagonist. P2Y14R is a genuine inflammatory target. The study tested it in mice with colitis and gouty arthritis and reported positive results.
But here's what the video leaves out:
-
The study is preclinical (mice + computer models), with 0 citations. "Revolutionary" is a stretch.
-
Multiple human RCTs found NO anti-inflammatory effect. A 24-month trial (300mg/day) in Type 1 diabetics showed no change in inflammatory markers. A 12-week trial (900mg/day) in diabetic nephropathy found no effect on inflammation. The BOND study (12 months, 600mg/day) found no effect on neuropathy outcomes.
-
The creator, Dr. Rick Pescatore, founded BellyMD, a supplement company selling benfotiamine products. This financial relationship is not disclosed in the video.
Benfotiamine is real, safe, and inexpensive. The preclinical anti-inflammatory science is genuine. But human trials have not confirmed the anti-inflammatory claims, and the "breakthrough" framing serves a product the creator sells.
Read more: https://pmc.ncbi.nlm.nih.gov/articles/PMC3329837/ https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040427 https://doi.org/10.1136/bmjdrc-2025-005773

















